Trial Profile
A Pivotal phase III trial of SPN-604 (Oxtellar XR) for Bipolar disorders
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Bipolar disorders
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 25 Feb 2020 According to Supernus Pharmaceuticals media release, the Company expects enrollment in the trial to continue through 2021.
- 05 Nov 2019 According to Supernus Pharmaceuticals media release, this trial has been initiated in the fourth quarter of 2019.
- 05 Nov 2019 Status changed from planning to recruiting, according to Supernus Pharmaceuticals media release.